scholarly journals ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association

EP Europace ◽  
2012 ◽  
Vol 14 (8) ◽  
pp. 1094-1103 ◽  
Author(s):  
E. Arbelo ◽  
J. Brugada ◽  
G. Hindricks ◽  
A. Maggioni ◽  
L. Tavazzi ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Pilot Study ◽  
Research Programme ◽  
Heart Rhythm ◽  
Atrial Fibrillation Ablation

scholarly journals In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences

EP Europace ◽  
2019 ◽  
Vol 22 (1) ◽  
pp. 66-73 ◽  
Author(s):  
Mihaela Grecu ◽  
Carina Blomström-Lundqvist ◽  
Josef Kautzner ◽  
Cecile Laroche ◽  
Isabelle C Van Gelder ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Sex Differences ◽  
Research Programme ◽  
Heart Rhythm ◽  
Neurological Complications ◽  
Cardiovascular Complications ◽  
Atrial Fibrillation Ablation ◽  
Improved Outcomes ◽  
Diabetes And Obesity

Abstract Aim The purpose of this study was to compare sex differences of atrial fibrillation (AF) catheter ablation (CA) and to analyse the opportunities for improved outcomes. Methods and results All data were collected from the Atrial Fibrillation Ablation Long-Term registry, a prospective, multinational study conducted by the ESC-EORP European Heart Rhythm Association (EHRA) under the EURObservational Research Programme (ESC-EORP). A total of 104 centres in 27 European countries participated. Of 3593 included patients, 1146 (31.9%) were female. Female patients were older (61.0 vs. 56.4 years; P < 0.001), had more comorbidities (hypertension, diabetes, and obesity), more episodes of arrhythmias per month (6.9 vs. 6.2; P < 0.001), and a higher average EHRA score (2.6 vs. 2.4; P < 0.001). The duration of the procedure was shorter in females (160.1 min vs. 167.9 min; P < 0.001), irrespective of additional ablation lesions added to pulmonary vein isolation. Overall cardiovascular complications were more frequent in women than in men (5.7% vs. 3.4%; P < 0.001). Furthermore, cardiac perforations (3.8% vs. 1.3%; P = 0.011) and neurological complications (2.2% vs. 0.3%; P = 0.004) were found in females in less experienced centres than in experienced ones. On a final note, at 12 months, AF recurrence rate was similar in females and males (34.4% vs. 34.2%; P = 0.897), but more females were still on antiarrhythmic drugs (50.6% vs. 44.1%; P < 0.001) when compared with men. Conclusion Females underwent CA procedures for AF less frequently than males throughout Europe, despite more recurrent symptoms. With the same success rate, severe acute complications remained considerable in females, especially in less experienced centres.

scholarly journals Direct oral anticoagulants in atrial fibrillation patients aged 75 years or older: Efficacy and safety balance

2017 ◽  
Vol 89 (4) ◽  
pp. 4-7 ◽  
Author(s):  
V V Fomin ◽  
A A Svistunov ◽  
D A Napalkov ◽  
A A Sokolova ◽  
M A Gabitova
Keyword(s):  
Atrial Fibrillation ◽  
Elderly Patients ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Research Programme ◽  
Heart Rhythm ◽  
Scientific Data ◽  
Treatment And Prevention ◽  
Heart Rhythm Disorders ◽  
Prevention Of Thromboembolic Events

Atrial fibrillation (AF) is one of the most common heart rhythm disorders in the population. Researchers revealed a direct relationship between their incidence and a patient’s age long ago. One of the most challenging issues of clinical practice in patients with AF is anticoagulant therapy used in the so-called very elderly patients aged 75 years and older when age itself is a risk factor for developing both thromboembolic and hemorrhagic events due to anticoagulants, regardless of the mechanism of action of the latter. However, scientific data regarding the treatment and prevention of thromboembolic events in elderly and senile patients with AF are very scarce and often uninformative. The data from the EURObservational Research Programme-Atrial Fibrillation Registry Pilot Phase (EORP-AF Pilot) and the randomized clinical studies RELY, ROCKET AF, ARISTOTLE, and AVERROES were analyzed to identify the most safe and most effective anticoagulant for elderly patients (over 75 years). Relying on the analyses of literature data, the authors propose an algorithm based on clinical characteristics for choosing the anticoagulant for patients older than 75 years.

scholarly journals Antiarrhythmic drug therapy after atrial fibrillation ablation: data of the ESC-EHRA registry

2020 ◽  
Vol 25 (5) ◽  
pp. 3874
Author(s):  
E. N. Mikhaylov ◽  
L. E. Korobchenko ◽  
S. A. Bayramova ◽  
V. E. Kharats ◽  
O. N. Kachalkova ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Research Programme ◽  
Atrial Fibrillation Ablation ◽  
Antiarrhythmic Agents ◽  
Clinical Predictors ◽  
Antiarrhythmic Drug Therapy ◽  
Factors Associated ◽  
Minimum Number

Aim. Catheter ablation (CA) is an effective approach for rhythm control in atrial fibrillation (AF), however antiarrhythmic therapy (AAT) remains important. There is a lack of data about long-term AAT use after CA. This study evaluates AAT after CA for AF.Material and methods. In 2012-2016, EURObservational Research Programme of Atrial Fibrillation Ablation Long-Term (EORP AFA L-T) registry was conducted, which included 476 Russian patients (57,1% — men; mean age — 57,1±8,7 years). The follow-up after CA was 12 months (available in 81,9% of patients). The use of AAT was evaluated prior to hospitalization, during hospitalization for CA, as well as at 3, 6 and 12 months of follow-up.Results. Prior to CA, 439 (92,2%) patients received AAT During CA, 459 (96,4%) patients were treated with AAT. After CA, AAT was used by 463 (97,3%), 370 (94,8%), and 307 (78,7%) patients at 3, 6 and 12 months of follow-up, respectively. There was no arrhythmia recurrence in 187 (47,9%) subjects. Among these patients, 40 (21,4%) received class IC or III AAT. The peak of AAT use was found for class IC agents within 3 months after CA (P<0,05), while for other drugs this trend was not observed. There were no factors associated with AAT usage in patients without arrhythmia recurrence after CA. A positive correlation of arrhythmia non-recurrence with a minimum number of previously used antiarrhythmic agents was revealed (RR=0,85; 95% CI 0,73-0,98; P=0,03).Conclusion. The frequency of AAT use after AF ablation is significantly reduced. However, there is a cohort of patients without documented arrhythmia recurrence still receiving AAT, which requires special attention of physicians. There were no clinical predictors of continued AAT in subjects without arrhythmia recurrence.

Association between Symptoms, Affect and Heart Rhythm in Patients with Persistent or Paroxysmal Atrial Fibrillation: An Ambulatory Pilot Study

2021 ◽  
Author(s):  
Kevin M Wheelock ◽  
Anna Kratz ◽  
Sangeeta Lathkar-Pradhan ◽  
Kayvan Najarian ◽  
Jonathan Gryak ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Pilot Study ◽  
Paroxysmal Atrial Fibrillation ◽  
Heart Rhythm

scholarly journals Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries

EP Europace ◽  
2019 ◽  
Vol 22 (2) ◽  
pp. 250-258 ◽  
Author(s):  
Roland Richard Tilz ◽  
Nikolaos Dagres ◽  
Elena Arbelo ◽  
Carina Blomström-Lundqvist ◽  
Harry J Crijns ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Heart Rhythm ◽  
Left Ventricular ◽  
Atrial Fibrillation Ablation ◽  
Left Ventricular Ejection ◽  
Web Based ◽  
Ventricular Ejection Fraction ◽  
Af Ablation ◽  
Atrial Size

Abstract Aims Rhythm control management in patients with atrial fibrillation (AF) may be unequal across Europe. The aim of this study was to investigate how selective the patient cohort referred for AF ablation is, as compared to the general AF population in Europe, and to describe the governing mechanisms for such selection. Methods and results Descriptive comparative statistical analyses of the baseline characteristics were performed between the cohorts of Atrial Fibrillation Ablation Long-Term (ESC EORP AFA-LT) registry, designed to provide a picture of contemporary real-world AF ablation, and the AF population from the AF-General (ESC EORP AF-Gen) pilot registry. Data collection was performed using a web-based system. In the AFA and in the Atrial Fibrillation General (AFG) pilot registries, 3593 and 3049 patients were enrolled, respectively. Patients who underwent AF ablation were younger, more commonly male, and had significantly less comorbidities. Atrial Fibrillation Ablation patients often presented without comorbidities, resulting in a lower risk of stroke (CHA2DS2-VASc ≥5: 2.9% vs. 24.5%, all P &lt; 0.001) and bleeding (HAS-BLED ≥2: 8.5% vs. 40.5%, P &lt; 0.001) but with European Heart Rhythm Association (EHRA) scores &gt;1 and more prevalent AF-related symptoms such as palpitations, fatigue, and weakness (all P &lt; 0.001) as compared to the general AF patients. Atrial Fibrillation Ablation patients were significantly more often male, had higher left ventricular ejection fraction (59.5% vs. 52.4%) and smaller left atrial size on echocardiogram (P &lt; 0.001 each). Conclusion The comparison of the patient cohorts in the AFA and AFG registries showed that AF ablation in European clinical practice is mostly performed in relatively young, symptomatic and relatively healthy patients.

Sign in / Sign up

Export Citation Format

Share Document